p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics.

Publisher: BioMed Central Country of Publication: England NLM ID: 101170464 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-811X (Electronic) Linking ISSN: 1478811X NLM ISO Abbreviation: Cell Commun Signal Subsets: MEDLINE

Original Publication: [London] : BioMed Central, c2003-

Pulmonary Disease, Chronic Obstructive*/drug therapy; Humans

Background: Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar remodeling. Although the abnormalities are primarily prompted by chronic exposure to inhaled irritants, maladjusted and self-reinforcing immune responses are significant contributors to the development and progression of the disease. The p38 isoforms are regarded as pivotal hub proteins that regulate immune and inflammatory responses in both healthy and disease states. As a result, their inhibition has been the subject of numerous recent studies exploring their therapeutic potential in COPD.
Main Body: We performed a systematic search based on the PRISMA guidelines to find relevant studies about P38 signaling in COPD patients. We searched the PubMed and Google Scholar databases and used "P38" AND "COPD" Mesh Terms. We applied the following inclusion criteria: (1) human, animal, ex vivo and in vitro studies; (2) original research articles; (3) published in English; and (4) focused on P38 signaling in COPD pathogenesis, progression, or treatment. We screened the titles and abstracts of the retrieved studies and assessed the full texts of the eligible studies for quality and relevance. We extracted the following data from each study: authors, year, country, sample size, study design, cell type, intervention, outcome, and main findings. We classified the studies according to the role of different cells and treatments in P38 signaling in COPD.
Conclusion: While targeting p38 MAPK has demonstrated some therapeutic potential in COPD, its efficacy is limited. Nevertheless, combining p38 MAPK inhibitors with other anti-inflammatory steroids appears to be a promising treatment choice. Clinical trials testing various p38 MAPK inhibitors have produced mixed results, with some showing improvement in lung function and reduction in exacerbations in COPD patients. Despite these mixed results, research on p38 MAPK inhibitors is still a major area of study to develop new and more effective therapies for COPD. As our understanding of COPD evolves, we may gain a better understanding of how to utilize p38 MAPK inhibitors to treat this disease. Video Abstract.
(© 2023. The Author(s).)

Biochim Biophys Acta. 2007 Aug;1773(8):1358-75. (PMID: 17481747)
Respir Res. 2012 Mar 14;13:20. (PMID: 22417244)
Oxid Med Cell Longev. 2021 Mar 19;2021:6668971. (PMID: 33824697)
Biochimie. 2019 Jan;156:47-58. (PMID: 30268700)
Am J Respir Cell Mol Biol. 2007 Apr;36(4):480-90. (PMID: 17099140)
Expert Opin Ther Pat. 2011 Dec;21(12):1843-66. (PMID: 22082194)
Am J Respir Cell Mol Biol. 2004 Dec;31(6):633-42. (PMID: 15333327)
Am J Respir Cell Mol Biol. 2013 Apr;48(4):518-30. (PMID: 23333920)
Sci Rep. 2015 Mar 04;5:8733. (PMID: 25736434)
Respir Med. 2009 Feb;103(2):230-6. (PMID: 18945604)
PLoS One. 2018 Mar 22;13(3):e0194197. (PMID: 29566026)
Eur Respir J. 2005 May;25(5):797-803. (PMID: 15863635)
Eur Respir J. 2018 Dec 6;52(6):. (PMID: 30309976)
Int J Mol Sci. 2022 Nov 12;23(22):. (PMID: 36430467)
Eur J Pharmacol. 2021 Jan 5;890:173654. (PMID: 33068589)
Respir Res. 2010 Jun 15;11:77. (PMID: 20550701)
PLoS Med. 2004 Oct;1(1):e8. (PMID: 15526056)
Respirology. 2015 Jul;20(5):722-9. (PMID: 25868842)
Int J Biochem Cell Biol. 2014 Aug;53:77-88. (PMID: 24853773)
Chin Med J (Engl). 2011 Feb;124(4):599-605. (PMID: 21362288)
Expert Rev Respir Med. 2020 May;14(5):485-491. (PMID: 32077346)
Exp Cell Res. 2019 May 15;378(2):182-190. (PMID: 30880028)
BMC Pulm Med. 2019 Feb 6;19(1):29. (PMID: 30727993)
Thorax. 2013 Aug;68(8):705-6. (PMID: 23611882)
Adv Exp Med Biol. 2018;1109:1-3. (PMID: 30523585)
Eur Respir J. 2013 Jul;42(1):28-41. (PMID: 23060629)
J Pharmacol Exp Ther. 2010 Dec;335(3):788-98. (PMID: 20801891)
JCI Insight. 2021 Jun 22;6(12):. (PMID: 34156029)
Int Immunopharmacol. 2021 Mar;92:107044. (PMID: 33461161)
Chest. 2013 Jul;144(1):266-273. (PMID: 23880677)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Exp Lung Res. 2008 Nov;34(9):599-629. (PMID: 19005923)
Toxicol In Vitro. 2021 Dec;77:105249. (PMID: 34560245)
Future Med Chem. 2011 Oct;3(13):1635-45. (PMID: 21942253)
Nat Rev Immunol. 2006 Jul;6(7):532-40. (PMID: 16799472)
Nat Rev Dis Primers. 2015 Dec 03;1:15076. (PMID: 27189863)
Trends Immunol. 2010 Aug;31(8):318-24. (PMID: 20620114)
Expert Opin Ther Pat. 2023 Jan-Jun;33(6):421-444. (PMID: 37501497)
J Bone Miner Metab. 2022 Nov;40(6):927-939. (PMID: 36163519)
Exp Mol Med. 2018 Jul 6;50(7):1-9. (PMID: 29980681)
Front Immunol. 2021 Sep 24;12:753940. (PMID: 34630433)
Am J Cardiovasc Drugs. 2014 Jun;14(3):155-65. (PMID: 24504769)
Am J Physiol Cell Physiol. 2006 Jul;291(1):C34-9. (PMID: 16467404)
Pharmacol Res Perspect. 2015 Feb;3(1):e00094. (PMID: 25692013)
Front Oncol. 2019 Nov 15;9:1146. (PMID: 31799175)
Thorax. 2014 Jul;69(7):666-72. (PMID: 24310110)
Curr Opin Pharmacol. 2012 Jun;12(3):287-92. (PMID: 22365729)
Am J Respir Cell Mol Biol. 2009 Dec;41(6):631-8. (PMID: 19717810)
Am J Pathol. 2016 Oct;186(10):2519-31. (PMID: 27555112)
Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902. (PMID: 11053025)
Lancet Respir Med. 2014 Jan;2(1):63-72. (PMID: 24461903)
Methods Mol Med. 2005;117:115-27. (PMID: 16118449)
Int J Chron Obstruct Pulmon Dis. 2016 Apr 29;11:909-17. (PMID: 27199554)
Eur Respir J. 2017 Oct 26;50(4):. (PMID: 29074542)
Curr Opin Pulm Med. 2022 Jul 1;28(4):296-302. (PMID: 35749794)
Am J Respir Crit Care Med. 1997 Nov;156(5):1633-9. (PMID: 9372687)
J Pharmacol Exp Ther. 2009 Feb;328(2):458-68. (PMID: 19004925)
Biochem Pharmacol. 2013 Oct 1;86(7):896-903. (PMID: 23948065)
Lancet Respir Med. 2023 Jan;11(1):18. (PMID: 36462509)
Am J Respir Crit Care Med. 2011 May 1;183(9):1176-86. (PMID: 21257786)
J Biol Chem. 2007 Oct 26;282(43):31398-408. (PMID: 17724032)
Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. (PMID: 25599809)
Am J Respir Crit Care Med. 2019 Sep 1;200(5):556-564. (PMID: 30860857)
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1358-66. (PMID: 21885626)
FASEB J. 2013 Jun;27(6):2367-81. (PMID: 23463699)
J Exp Med. 2006 Aug 7;203(8):1883-9. (PMID: 16880258)
Cell Physiol Biochem. 2016;39(2):685-92. (PMID: 27442627)
Int J Chron Obstruct Pulmon Dis. 2015 Feb 04;10:283-91. (PMID: 25678784)
Nat Rev Immunol. 2018 Jul;18(7):454-466. (PMID: 29626211)
Front Pharmacol. 2022 Sep 28;13:950035. (PMID: 36249771)
Chest. 2003 Jul;124(1):323-7. (PMID: 12853540)
Front Immunol. 2020 Apr 28;11:532. (PMID: 32411122)
Thorax. 2001 Jun;56(6):420-2. (PMID: 11359954)
Eur Respir J. 2008 Jan;31(1):62-9. (PMID: 17959643)
Thorax. 2002 Jul;57(7):590-5. (PMID: 12096201)
Chest. 2011 Jun;139(6):1470-1479. (PMID: 21652557)
Respir Med. 2017 Sep;130:20-26. (PMID: 29206629)
Lancet Respir Med. 2022 May;10(5):512-524. (PMID: 35427533)
Eur Respir J. 2007 Sep;30(3):467-71. (PMID: 17504799)
Med Sci Monit. 2013 Dec 31;19:1229-35. (PMID: 24382347)
Nat Rev Immunol. 2018 Feb;18(2):134-147. (PMID: 28990587)
Eur Respir J. 2017 Nov 30;50(5):. (PMID: 29191950)
Transl Res. 2013 Sep;162(3):156-73. (PMID: 23831269)
Int J Chron Obstruct Pulmon Dis. 2018 Apr 11;13:1135-1144. (PMID: 29692608)
Thorax. 2009 Dec;64(12):1044-52. (PMID: 19850966)
Allergol Immunopathol (Madr). 2022 Sep 01;50(5):47-56. (PMID: 36086963)
Drug Des Devel Ther. 2021 Mar 23;15:1275-1284. (PMID: 33790539)
J Immunol. 2001 Aug 15;167(4):2040-8. (PMID: 11489986)
Int J Chron Obstruct Pulmon Dis. 2018 Oct 18;13:3399-3410. (PMID: 30425469)
Biochem Biophys Res Commun. 2010 May 28;396(2):555-61. (PMID: 20438701)
Nat Rev Immunol. 2022 Sep;22(9):576-588. (PMID: 35288707)
Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L566-77. (PMID: 12618418)
Front Mol Neurosci. 2020 Sep 08;13:570586. (PMID: 33013322)
J Allergy Clin Immunol. 2008 May;121(5):1238-1245.e4. (PMID: 18355907)
Expert Opin Investig Drugs. 2008 Oct;17(10):1411-25. (PMID: 18808304)
N Engl J Med. 2004 Jun 24;350(26):2645-53. (PMID: 15215480)
Br J Pharmacol. 2012 Aug;166(7):2070-83. (PMID: 22352763)
Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1174-86. (PMID: 18375740)
FASEB J. 2019 Feb;33(2):1605-1616. (PMID: 30156909)
Cell Res. 2005 Jan;15(1):11-8. (PMID: 15686620)
Int J Chron Obstruct Pulmon Dis. 2018 Mar 27;13:1009-1019. (PMID: 29628759)
J Bras Pneumol. 2022 Dec 02;48(6):e20220183. (PMID: 36477172)
Int J Mol Sci. 2020 Mar 11;21(6):. (PMID: 32168915)
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. (PMID: 36856433)
Mol Med Rep. 2013 Dec;8(6):1683-8. (PMID: 24126384)
Blood. 2016 Nov 10;128(19):2327-2337. (PMID: 27609642)
Ther Adv Respir Dis. 2008 Dec;2(6):351-74. (PMID: 19124382)
Front Immunol. 2021 Aug 10;12:708770. (PMID: 34447377)
Biochem J. 2010 Aug 1;429(3):403-17. (PMID: 20626350)
Nature. 2015 Dec 17;528(7582):413-7. (PMID: 26649828)
Int J Tuberc Lung Dis. 2010 Sep;14(9):1079-86. (PMID: 20819250)
Proc Am Thorac Soc. 2006 Jun;3(4):377-82. (PMID: 16738204)
Am J Physiol Cell Physiol. 2018 Jan 1;314(1):C73-C87. (PMID: 27413169)
Front Med (Lausanne). 2021 Apr 27;8:616200. (PMID: 33987189)
PLoS One. 2016 Sep 28;11(9):e0163139. (PMID: 27680884)
Mol Med. 2021 Sep 3;27(1):97. (PMID: 34479474)
Cancer Cell. 2009 Sep 8;16(3):183-94. (PMID: 19732719)
Mol Cell Biol. 2005 Dec;25(23):10454-64. (PMID: 16287858)
Respirology. 2008 Mar;13(2):203-14. (PMID: 18339017)
Blood. 2016 Nov 10;128(19):2280-2282. (PMID: 28829751)
Int J Chron Obstruct Pulmon Dis. 2018 Apr 19;13:1279-1288. (PMID: 29719383)
Trends Mol Med. 2021 Apr;27(4):314-331. (PMID: 33309601)
Biochem Biophys Res Commun. 2010 Feb 26;393(1):137-43. (PMID: 20117097)
J Clin Pharmacol. 2010 Jan;50(1):94-100. (PMID: 19880675)
N Engl J Med. 2015 Jul 9;373(2):111-22. (PMID: 26154786)
J Pharmacol Exp Ther. 2011 Sep;338(3):732-40. (PMID: 21610141)
Am J Respir Cell Mol Biol. 2008 May;38(5):600-8. (PMID: 18079491)
Eukaryot Cell. 2007 Oct;6(10):1701-14. (PMID: 17715363)
Respir Med. 2023 Sep;216:107294. (PMID: 37295536)
BMC Pulm Med. 2014 May 07;14:79. (PMID: 24885161)
J Recept Signal Transduct Res. 2014 Aug;34(4):299-306. (PMID: 24593255)
J Clin Pharmacol. 2012 Mar;52(3):416-24. (PMID: 22090363)
Free Radic Biol Med. 2023 Aug 20;205:129-140. (PMID: 37257701)
Biomolecules. 2021 Mar 04;11(3):. (PMID: 33806618)
Br J Pharmacol. 2006 Oct;149(4):393-404. (PMID: 16953188)
Chest. 2023 Jul;164(1):69-84. (PMID: 36907372)
Am J Respir Cell Mol Biol. 2023 Nov;69(5):500-507. (PMID: 37584669)
J Allergy Clin Immunol. 2015 Sep;136(3):531-45. (PMID: 26343937)
Front Immunol. 2021 Apr 19;12:597595. (PMID: 33953706)
Int Immunopharmacol. 2021 May;94:107427. (PMID: 33571746)
Eur Respir J. 2007 Jan;29(1):42-50. (PMID: 17050556)
Chest. 2008 Aug;134(2):394-401. (PMID: 18682458)
Respir Res. 2011 Oct 05;12:130. (PMID: 21970519)
Int Immunopharmacol. 2012 Jan;12(1):26-33. (PMID: 22032841)
Respir Res. 2011 Jun 10;12:78. (PMID: 21663649)
J Clin Med. 2019 Nov 22;8(12):. (PMID: 31766770)
Respiration. 2015;89(4):329-42. (PMID: 25791156)
J Biol Chem. 2003 Feb 14;278(7):4831-9. (PMID: 12475989)
Nat Immunol. 2005 Apr;6(4):390-5. (PMID: 15735648)
Mediators Inflamm. 2014;2014:352371. (PMID: 24771982)
Thorax. 2015 Dec;70(12):1189-96. (PMID: 26286722)
Thorax. 2014 Jan;69(1):5-13. (PMID: 23980116)
Environ Health Perspect. 2002 Jul;110(7):715-20. (PMID: 12117649)
Thorax. 2013 Aug;68(8):738-45. (PMID: 23539534)
Proc Am Thorac Soc. 2006 Aug;3(6):494-8. (PMID: 16921126)
Biochem Biophys Res Commun. 2014 Jul 18;450(1):110-6. (PMID: 24866242)
J Biol Chem. 2007 Jan 12;282(2):908-15. (PMID: 17099219)
Cell Biochem Biophys. 2007;49(2):98-110. (PMID: 17906365)
BMC Pharmacol Toxicol. 2012 Nov 13;13:15. (PMID: 23148608)
Blood. 2022 Aug 25;140(8):889-899. (PMID: 35679477)
J Immunol. 2006 Jun 1;176(11):7028-38. (PMID: 16709865)
COPD. 2019 Dec;16(5-6):344-353. (PMID: 31682162)

Keywords: COPD; COPD pharmacotherapy; Chronic Obstructive Pulmonary Disease; Systematic review; p38 MAPK inhibitors; p38 MAPK signaling
Local Abstract: [plain-language-summary] We wanted to determine what studies have been done on how a protein called p38 affects a lung disease called COPD. COPD is a condition that makes it hard to breathe and can cause coughing, wheezing, and chest infections. p38 is a protein that helps cells to respond to stress and inflammation, but it may also play a role in causing or worsening COPD. We searched two main online databases for studies that met our criteria. We looked for studies that involved humans, studies that used animals or cells in the lab, studies that reported new findings, studies that were written in English, and studies that focused on p38 and COPD. We did not include studies that were reviews, summaries, opinions, or letters or studies that were not related to p38 or COPD. We found 361 studies that matched our criteria. We read the titles and summaries of these studies and checked the full texts for quality and relevance. We collected information from each study, such as who did it, when and where it was done, how many people were involved, what type of cells were studied, what treatment was given, what outcome was measured, and what the main results were. We grouped the studies based on the type of cells and type of treatment they studied. We found that different types of cells (such as lung cells, immune cells, and blood cells) and different types of treatment can affect how p38 works in COPD.

Date Created: 20231103 Date Completed: 20231113 Latest Revision: 20231113

20231114

PMC10623820

10.1186/s12964-023-01337-4

37919729